Efficacy of proinflamatory cytokines in the clinical and radiograpic outcomes of different primary molar pulpotomy agents: a comperative randomised study featuring a novel biomarker for pulpal diagnosis.
Humans
Pulpotomy
/ methods
Biomarkers
/ analysis
Child
Molar
Female
Male
Silicates
/ therapeutic use
Calcium Compounds
/ therapeutic use
Interleukin-6
/ analysis
Interleukin-8
/ analysis
Pulpitis
Tooth, Deciduous
Drug Combinations
Oxides
/ therapeutic use
Aluminum Compounds
/ therapeutic use
Pulp Capping and Pulpectomy Agents
/ therapeutic use
Treatment Outcome
Cytokines
/ analysis
Presepsin
Pulpal inflammation
Pulpotomy agents
Pulpotomy treatment
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
18
07
2024
accepted:
26
09
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
15
10
2024
Statut:
epublish
Résumé
While the effect of biomaterials covering the pulp tissue is considered in the success of pulpotomy treatment, the level of pulpal inflammation is still very important for treatment success. The aim of this study was to compare IL-6 and IL-8 levels, known as good indicators of pulpal inflammation, with a new biomarker, presepsin, and to evaluate the impact of biomarker levels along with the pulp capping agents used in the treatment on the one-year success of pulpotomy treatment. The study included 120 primary second molar teeth with pulpotomy indications from 75 children. To determine the pulpal inflammation status, pulpal bleeding samples were taken during treatment, and the levels of IL-6, IL-8, and presepsin were measured. During the pulpotomy treatment, MTA, NeoMTA™, and Biodentine™, and ZOE were randomly applied to groups of thirty teeth each. Patients were monitored for a period of 12 months post-treatment. IL-8, IL-6, and presepsin levels were significantly higher in teeth with pathology (p < 0.001). Biomarker levels were found to be higher in the NeoMTA and Biodentine groups, but this did not result in a statistically significant difference. (p > 0.05) Following pulpotomy treatment, the most successful material groups in order were MTA, ZOE, NeoMTA™, and Biodentine™. Presepsin may be a usable indicator in predicting the level of inflammation. At the end of the one-year follow-up of pulpotomy treatment, more pathology was observed in the NeoMTA and Biodentine groups, where biomarker levels were higher, while no pathology was found in the MTA group, where biomarker levels were lower. NCT06398327/ 20,240,503.
Sections du résumé
BACKGROUND
BACKGROUND
While the effect of biomaterials covering the pulp tissue is considered in the success of pulpotomy treatment, the level of pulpal inflammation is still very important for treatment success. The aim of this study was to compare IL-6 and IL-8 levels, known as good indicators of pulpal inflammation, with a new biomarker, presepsin, and to evaluate the impact of biomarker levels along with the pulp capping agents used in the treatment on the one-year success of pulpotomy treatment.
METHODS
METHODS
The study included 120 primary second molar teeth with pulpotomy indications from 75 children. To determine the pulpal inflammation status, pulpal bleeding samples were taken during treatment, and the levels of IL-6, IL-8, and presepsin were measured. During the pulpotomy treatment, MTA, NeoMTA™, and Biodentine™, and ZOE were randomly applied to groups of thirty teeth each. Patients were monitored for a period of 12 months post-treatment.
RESULTS
RESULTS
IL-8, IL-6, and presepsin levels were significantly higher in teeth with pathology (p < 0.001). Biomarker levels were found to be higher in the NeoMTA and Biodentine groups, but this did not result in a statistically significant difference. (p > 0.05) Following pulpotomy treatment, the most successful material groups in order were MTA, ZOE, NeoMTA™, and Biodentine™.
CONCLUSION
CONCLUSIONS
Presepsin may be a usable indicator in predicting the level of inflammation. At the end of the one-year follow-up of pulpotomy treatment, more pathology was observed in the NeoMTA and Biodentine groups, where biomarker levels were higher, while no pathology was found in the MTA group, where biomarker levels were lower.
TRIAL REGISTRATION
BACKGROUND
NCT06398327/ 20,240,503.
Identifiants
pubmed: 39407247
doi: 10.1186/s12903-024-04972-6
pii: 10.1186/s12903-024-04972-6
doi:
Substances chimiques
Biomarkers
0
Silicates
0
Calcium Compounds
0
Interleukin-6
0
mineral trioxide aggregate
0
Interleukin-8
0
Drug Combinations
0
Oxides
0
Aluminum Compounds
0
Pulp Capping and Pulpectomy Agents
0
tricalcium silicate
404G39282C
Cytokines
0
Banques de données
ClinicalTrials.gov
['NCT06398327']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227Subventions
Organisme : Unit of Scientific Research Projects - Ataturk University
ID : 10056
Informations de copyright
© 2024. The Author(s).
Références
Smaïl-Faugeron V, Glenny AM, Courson F, Durieux P, Muller-Bolla M, Fron Chabouis H. Pulp treatment for extensive decay in primary teeth. Cochrane Database Syst Rev. 2018;5(5):Cd003220.
pubmed: 29852056
Stringhini Junior E, Dos Santos MGC, Oliveira LB, Mercadé M. MTA and biodentine for primary teeth pulpotomy: a systematic review and meta-analysis of clinical trials. Clin Oral Investig. 2019;23(4):1967–76.
doi: 10.1007/s00784-018-2616-6
pubmed: 30238414
Ng FK, Messer LB. Mineral trioxide aggregate as a pulpotomy medicament: an evidence-based assessment. Eur Arch Paediatr Dent. 2008;9(2):58–73.
doi: 10.1007/BF03262612
pubmed: 18534173
Fuks ABPB. Pediatric Endodontics.Current concepts in Pulp Therapy for Primary and Young Permanent Teeth. In: Kaaren G, Vargas ABF, Benjamin Peretz, editors. Pulpotomy techniques: cervical (traditional) and partial. Israiel: Springer; 2016. pp. 51–70.
Ozdemir Y, Kutukculer N, Topaloglu-Ak A, Kose T, Eronat C. Comparative evaluation of pro-inflammatory cytokine levels in pulpotomized primary molars. J Oral Sci. 2015;57(2):145–50.
doi: 10.2334/josnusd.57.145
pubmed: 26062864
Elsalhy M, Azizieh F, Raghupathy R. Cytokines as diagnostic markers of pulpal inflammation. Int Endod J. 2013;46(6):573–80.
doi: 10.1111/iej.12030
pubmed: 23240887
Zehnder M, Delaleu N, Du Y, Bickel M. Cytokine gene expression–part of host defence in pulpitis. Cytokine. 2003;22(3–4):84–8.
doi: 10.1016/S1043-4666(03)00116-9
pubmed: 12849707
Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5(1):16–9.
doi: 10.5847/wjem.j.issn.1920-8642.2014.01.002
pubmed: 25215141
Guo J, Zhang N, Cheng Y. Comparative efficacy of medicaments or techniques for pulpotomy of primary molars: a network meta-analysis. Clin Oral Investig. 2023;27(1):91–104.
doi: 10.1007/s00784-022-04830-1
pubmed: 36580161
Bossù M, Iaculli F, Di Giorgio G, Salucci A, Polimeni A, Di Carlo S. Different pulp dressing materials for the pulpotomy of primary teeth: a systematic review of the literature. J Clin Med. 2020;9(3):838–61.
doi: 10.3390/jcm9030838
pubmed: 32204501
Juneja P, Kulkarni S. Clinical and radiographic comparison of biodentine, mineral trioxide aggregate and formocresol as pulpotomy agents in primary molars. Eur Arch Paediatr Dent. 2017;18(4):271–8.
doi: 10.1007/s40368-017-0299-3
pubmed: 28780718
Ahuja S, Surabhi K, Gandhi K, Kapoor R, Malhotra R, Kumar D. Comparative evaluation of success of Biodentine and Mineral Trioxide Aggregate with Formocresol as Pulpotomy medicaments in primary molars: an in vivo study. Int J Clin Pediatr Dent. 2020;13(2):167–73.
doi: 10.5005/jp-journals-10005-1740
pubmed: 32742096
Xavier MT, Costa AL, Caramelo FJ, Palma PJ, Ramos JC. Evaluation of the interfaces between restorative and regenerative biomaterials used in vital pulp therapy. Mater (Basel). 2021;14(17):5055.
doi: 10.3390/ma14175055
Donnermeyer D, Dammaschke T, Lipski M, Schäfer E. Effectiveness of diagnosing pulpitis: a systematic review. Internationa Endodontic J. 2022:1–30.
Michaelson PL, Holland GR. Is pulpitis painful? Int Endod J. 2002;35(10):829–32.
doi: 10.1046/j.1365-2591.2002.00579.x
pubmed: 12406376
AAPD. Guideline on Pulp Therapy for Primary and Immature Permanent Teeth. Pediatr Dent. 2016;38(6):280–8.
Matsuo T, Nakanishi T, Shimizu H, Ebisu S. A clinical study of direct pulp capping applied to carious-exposed pulps. J Endod. 1996;22(10):551–6.
doi: 10.1016/S0099-2399(96)80017-3
pubmed: 9198445
Farges JC, Keller JF, Carrouel F, Durand SH, Romeas A, Bleicher F, et al. Odontoblasts in the dental pulp immune response. J Exp Zool Part B. 2009;312b(5):425–36.
doi: 10.1002/jez.b.21259
Hirsch V, Wolgin M, Mitronin AV, Kielbassa AM. Inflammatory cytokines in normal and irreversibly inflamed pulps: a systematic review. Arch Oral Biol. 2017;82:38–46.
doi: 10.1016/j.archoralbio.2017.05.008
pubmed: 28600966
Memar MY, Baghi HB, Presepsin. A promising biomarker for the detection of bacterial infections. Biomed Pharmacother. 2019;111:649–56.
doi: 10.1016/j.biopha.2018.12.124
pubmed: 30611989
Gopinath VK, Anwar K. Histological evaluation of pulp tissue from second primary molars correlated with clinical and radiographic caries findings. Dent Res J (Isfahan). 2014;11(2):199–203.
pubmed: 24932190
Vashist S. Immunodiagnostics: major advances and future insights. J Biochips Tiss Chips. 2013;3(105):2153–77.
Sorsa T, Gursoy UK, Nwhator S, Hernandez M, Tervahartiala T, Leppilahti J, et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases. Periodontol 2000. 2016;70(1):142–63.
doi: 10.1111/prd.12101
pubmed: 26662488
Shafaee H, Alirezaie M, Rangrazi A, Bardideh E. Comparison of the success rate of a bioactive dentin substitute with those of other root restoration materials in pulpotomy of primary teeth: systematic review and meta-analysis. J Am Dent Assoc. 2019;150(8):676–88.
doi: 10.1016/j.adaj.2019.03.002
pubmed: 31202439
Bani M, Aktaş N, Çınar Ç, Odabaş ME. The clinical and radiographic success of primary molar pulpotomy using Biodentine™ and Mineral Trioxide Aggregate: a 24-Month Randomized Clinical Trial. Pediatr Dent. 2017;39(4):284–8.
pubmed: 29122067
Cuadros-Fernández C, Lorente Rodríguez AI, Sáez-Martínez S, García-Binimelis J, About I, Mercadé M. Short-term treatment outcome of pulpotomies in primary molars using mineral trioxide aggregate and Biodentine: a randomized clinical trial. Clin Oral Invest. 2016;20(7):1639–45.
doi: 10.1007/s00784-015-1656-4
Alsanouni M, Bawazir OA. A Randomized Clinical Trial of NeoMTA plus in primary molar pulpotomies. Pediatr Dent. 2019;41(2):107–11.
pubmed: 30992107
Cordell S, Kratunova E, Marion I, Alrayyes S, Alapati SB. A randomized controlled trial comparing the success of Mineral Trioxide Aggregate and Ferric Sulfate as Pulpotomy medicaments for primary molars. J Dent Child. 2021;88(2):120–8.
Pratima B, Chandan G, Nidhi T, Nitish I, Sankriti M, Nagaveni S, et al. Postoperative assessment of diode laser zinc oxide eugenol and mineral trioxide aggregate pulpotomy procedures in children: a comparative clinical study. J Indian Soc Pedod Prev. 2018;36(3):308–14.
doi: 10.4103/JISPPD.JISPPD_1132_17
Gonzalez-Lara A, Ruiz-Rodriguez MS, Pierdant-Perez M, Garrocho-Rangel JA, Pozos-Guillen AJ. Zinc oxide–eugenol pulpotomy in primary teeth: a 24-month follow-up. J Clin Pediatr Dent. 2016;40(2):107–12.
doi: 10.17796/1053-4628-40.2.107
pubmed: 26950810